A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Investegate |Arecor Therapeutics Announcements | Arecor Therapeutics: Arecor announces collaboration with Lilly
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
eureKARE launches with $60 million to build and finance next generation biotech companies in Europe
B
innovation
eureKARE
accompanied by a hig May 2021: eureKARE ( the Company ), a pioneering new company focused on financing and building next generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, today announces its launch with a $60 million Series A financing. The financing was supported by high-net worth investors and family offices.
eureKARE is focused on two emerging and cutting-edge fields of research that have the potential to disrupt and revolutionize the life sciences industry: the microbiome and synthetic biology. Up to 90% of all diseases can be linked to the dysfunction and imbalance of the microbiome with the field forecast to reach $1.6 billion by 2028 at a CAGR of 21%. Synthetic biology, which comprises gene and cell therapy and industrial applications such as data storage and bioproduction, has seen huge advances